Memo Therapeutics AG and Northway Biotechpharma sign a Development and Manufacturing Agreement

| Memo Therapeutics AG

Zurich, Switzerland, and Vilnius, Lithuania – June 25, 2020 – Memo Therapeutics AG and Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), have signed a Development and Manufacturing Agreement for a therapeutic antibody.

Memo Therapeutics AG aims to bring its lead Monoclonal Antibody MTX-005 for the immunotherapy of BK virus infection in kidney transplant recipients into clinical development in 2021. Northway Biotechpharma will develop the cell line and the manufacturing process, followed by cGMP manufacturing of Memo Therapeutics AG antibody for clinical studies.

“Infection with the BK virus is a serious threat to kidney transplant patients. We have identified a BK virus-neutralizing antibody with ultra high potency isolated from human donors for the treatment of BK virus infection after kidney transplantation. We have chosen Northway Biotechpharma due to its technical capabilities and expertise which is very important for the successful production of our antibody”, said Dr. Karsten Fischer, CEO of Memo Therapeutics AG.

Dr. Vladas Bumelis, Executive Chairman of the Board of Northway Biotechpharma, commented “I am very excited to start the cooperation with Memo Therapeutics AG on this promising antibody, supporting Memo´s program from cell line development up to drug product manufacturing”.


“Northway Biotechpharma is perfectly positioned to act as Memo Therapeutics AG´ cooperation partner for this project due to its high quality approach, its proven track record with similar programs and its outstanding customer focus combined with CMC guidance”, said Dr. André Markmann, VP Business Development of Northway Biotechpharma.


About Memo Therapeutics AG

Memo Therapeutics AG (MTx) is an innovator in the field of antibody discovery and immune repertoire analysis.

MTx’s antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity.

The platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells. The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing mAbs with the desired functional properties.

Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, the Company engages in antibody discovery across species and indications for proprietary and partnered projects.

MTx’s current pipeline features programs in infectious diseases and immuno-oncology.
MTx is a private company located in Bio-Technopark Zurich, Switzerland.

For more information, please visit


About Northway Biotechpharma -

Northway Biotechpharma is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company’s wide-ranging expertise and vertically integrated service offering translates to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities, while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotechpharma is a privately owned company founded in 2004 and located in Vilnius, Lithuania, and in Waltham, Boston, US.


For Further Information Contact: